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Background: Continued advances in human microbiome research and technologies raise a number of ethical,
legal, and social challenges. These challenges are associated not only with the conduct of the research, but also
with broader implications, such as the production and distribution of commercial products promising maintenance
or restoration of good physical health and disease prevention. In this article, we document several ethical, legal,
and social challenges associated with the commercialization of human microbiome research, focusing particularly
on how this research is mobilized within economic markets for new public health uses.
Methods: We conducted in-depth, semi-structured interviews (2009–2010) with 63 scientists, researchers, and
National Institutes of Health project leaders (“investigators”) involved with human microbiome research. Interviews
explored a range of ethical, legal, and social dimensions of human microbiome research, including investigators’
perspectives on commercialization. Using thematic content analysis, we identified and analyzed emergent themes
and patterns.
Results: Investigators discussed the commercialization of human microbiome research in terms of (1)
commercialization, probiotics, and issues of safety, (2) public awareness of the benefits and risks of dietary
supplements, and (3) regulation.
Conclusion: The prevailing theme of ethical, legal, social concern focused on the need to find a balance between
the marketplace, scientific research, and the public’s health. The themes we identified are intended to serve as
points for discussions about the relationship between scientific research and the manufacture and distribution of
over-the-counter dietary supplements in the United States.
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Qualitative researchBackground
Continued advances in human microbiome research and
technologies raise a number of ethical, legal, and social
challenges. These challenges are associated not only with
the conduct of the research itself, such as privacy, informed
consent, return of research results, invasiveness of sam-
pling, and participant diversity [1], but also with broader* Correspondence: melody.slashinski@bcm.edu
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reproduction in any medium, provided the orimplications ranging from health care services and delivery,
to peoples’ conceptions of health and disease, to the mass
production and distribution of commercial products prom-
ising maintenance or restoration of good physical health
and disease prevention. In this article we are concerned
with the latter implication. Drawing from a larger qualita-
tive study on the ethical, legal, and social dimensions of
human microbiome research, the findings we present here
focus on the commercialization of human microbiome
research, particularly the mobilization of this research
within economic markets for new public health uses.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is becoming increasingly common [2]. According to the
Institute of Medicine [3], the dietary supplements indus-
try is one of the fastest growing industries, developing
an annual average of 1,000 new products, and netting
billions of dollars in annual revenue. Dietary supple-
ments, including over-the-counter probiotic-containing
food products such as yogurt, cereal, and wellness bars,
are overwhelmingly marketed to a generally healthy
population [4] under the umbrella of functional foods, or
“whole foods and fortified, enriched, or enhanced foods
[that] have a potentially beneficial effect on health when
consumed as part of a varied diet on a regular basis, at
effective levels” [[5] p.735]. Marketing strategies promote
these added health benefits in terms of “vitality,”
“balance,” and “beauty,” and claim relief from digestive
irregularity to acne. Recent research on public perceptions
of these products suggests these strategies are lucrative, as
products are becoming essential to peoples’ preventative
health care regimens [2], and consumers generally perceive
these products as both safe and effective [6].
The growth of this industry introduces several ethical,
legal and social concerns about the commercialization of
human microbiome research. Notably, how dietary supple-
ments are mobilized within economic markets and gain so-
cial currency for new public health uses, often without
evidence to substantiate safety or effectiveness [7], and with
sparing regulation or oversight. We contend that the rela-
tionship between scientific research and commercialization
manifests in terms of both a perceived public value and a
marketable exchange value, or what sociologist Catherine
Waldby [8] refers to as biovalue. To illustrate, we consider
the commercial potential of large-scale human microbiome
research efforts, particularly the Human Microbiome Pro-
ject, that identify human microbial communities and good
bacteria as having “biological vitality” [[8] p. 310]. The pub-
lic value centers on expectations that these research efforts
will provide a “viable contribution to human health” [[8]
p. 310], while the marketable exchange value centers on
expectations that industry will profit substantially from nat-
ural or engineered biological commodities under the guise
of contributing to human health. To date, there is a dearth
of research as to how the commercialization of human
microbiome research might further compound the ethical,
legal, and social issues debated in the context of mainten-
ance or restoration of good physical health and the preven-
tion of disease or illness. Our purpose here is to begin to
explore and discuss some of these issues, and their broader
implications.
The Human Microbiome Project
The Human Microbiome Project (HMP), initiated in
2007 by the National Institutes of Health (NIH), aims
to characterize the role human microbiota, or thecollections of bacteria, viruses, and other microorgan-
isms that inhabit human bodies, play in human health
and disease. The HMP seeks to establish a relationship
between microbial communities and human health,
human behavior, and the environment, investigating
whether or not individuals share a core human micro-
biome, and whether or not changes in the human micro-
biome are correlated with changes in human health [9].
This large-scale, multi-site research effort was intended
to yield not only clinical [10], pharmaceutical [11], and
other public health [12] benefits, but also a reference set
of microbial genome sequences, a repository to store
biological materials, and new technologies, including
tools for computational analysis, interpretation, and the
Data Analysis and Coordinating Center (DACC) [13].
Since its inception, researchers studying the human
microbiome have associated the presence or absence of
certain good bacteria with a number of chronic and acute
conditions including atherosclerosis [14], inflammatory
bowel disease [15], colon cancer [16], irritable bowel syn-
drome [17], nonalcoholic fatty liver disease [18], and
perinatal and neonatal health [19]. Additionally, bioinfor-
maticists have developed specific tools and techniques to
analyze, interpret, and store these data [20-22].
Methods
Drawing from a larger qualitative study exploring the eth-
ical, legal, and social dimensions of human microbiome re-
search, the findings presented here emerged from 60 semi-
structured interviews we conducted with 63 scientists,
researchers, and NIH project leaders (“investigators”)
engaged in human microbiome research (2009–2010).
Semi-structured interviews allowed us to set the agenda in
terms of the topics we wanted to cover, while providing
investigators flexibility in their discussions and interpreta-
tions of these topics. These semi-structured interviews
lasted between 30 and 90 minutes, and consisted of a series
of open-ended questions exploring ethical, legal, and social
challenges associated with human microbiome research.
Topics discussed included investigator role; ethical chal-
lenges; clinical applications and future ethical clinical impli-
cations; precedents for managing ethical, legal, and social
issues; ethical, legal, and social issues unique to microbiome
research; and other topics as they arose see Additional file
1. In order to achieve a diverse sample of clinical, applied,
and research expertise, we employed two sampling strat-
egies. Initially, using a purposive sampling strategy [23], we
identified 140 potential investigators from a publicly access-
ible list of HMP Research Network Meeting Participants.
Subsequent snowball sampling [23] supplemented our re-
cruitment efforts, allowing us to interview investigators
who, for example, were not directly involved in the HMP
but were involved in human microbiome research. Eighty-
eight agreed to participate, 41 did not respond, and 11
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63 were interviewed in 60 distinct interviews (the remaining
25 were not interviewed due to scheduling conflicts).
Investigators represented a range of academic disciplines,
including genetics, pathology, microbiology, virology,
gastroenterology, and medicine.
All interviews were conducted in-person in the Baylor
College of Medicine Center for Medical Ethics and
Health Policy conference room, in investigators’ offices,
or during the January 2010 and August 2010 Human
Microbiome Consortium meetings (Houston, Texas and
St. Louis, Missouri, respectively). Interviews were digit-
ally recorded and transcribed verbatim by an independ-
ent transcriptionist service. We analyzed data (i.e.
interview transcripts) using thematic content analysis.
Two authors (MJS, LSA) independently coded tran-
scripts and reached consensus in coding [24] using
ATLAS.ti (v 6.2), a qualitative data analysis software pro-
gram. ATLAS.ti files were distributed to other members
of the research team for additional comment and coding.
To protect confidentiality, we refer to investigators using
an identification number (Investigator #), given in paren-
theses after quotations or references attributable to
them. Investigators provided verbal consent, and all pro-
cedures were reviewed and approved by the Baylor Col-
lege of Medicine Institutional Review Board and the
University of Texas Health Science Center Committee
for the Protection of Human Subjects. A comprehensive
explanation of our methods has been previously docu-
mented [25].
We limit our findings to the ethical, legal, and social
considerations raised by human microbiome research that
intersect with commercialization related issues, such as
safety, risks and benefits, public awareness, and regulation.
Below, we present each of these issues, paying particular
attention to the ethical, legal, and social aspects of
commercialization and human microbiome research. We
conclude considering broader implications for public
health and recommendations for policy change.
Results and Discussion
Commercialization, probiotics, and issues of safety
Human microbiome research is expected to provide a
valuable contribution to human health and disease pre-
vention. One area of interest centers on investigating the
utility of good bacteria, often delivered through pre-
biotic, probiotic, or promicrobial therapies and treat-
ments [26], for a range of acute and chronic diseases (i.e.
diseases of the gastrointestinal tract). These and similar
investigations bolster the scientific value of good bac-
teria, opening a door for “claims made by commercial
organizations [that] cite the Human Microbiome Project
and all of its findings as evidence that customers should
buy their product.” (Investigators #154) Investigatorsdescribed the ways in which these claims have the po-
tential to manifest in widespread commercialization of a
range of over-the-counter probiotics, for example:
I also see a huge push for probiotic anything. We
always joke about probiotic lotion, probiotic chewing
gum—I think they’ll try to work probiotics into
anything and everything they can. There’s data out
there that shows these communities are important.
They’re important in everything—from helping your
immune system get started to breaking down the food
that you eat, to just producing vitamins. So I really
think that probiotics will be huge. There’ll be many,
many more, and it will be for the craziest things but—
like, you think of probiotic shampoo. I bet they can
market probiotic shampoo to cure dandruff or
something. It will be something crazy. Jergens will
come out with probiotic lotion, and Extra chewing
gum. (Investigator #135)
Investigators recognized the currency of these com-
mercial products, thus they were attuned to the ways in
which scientific value is mobilized within markets to
yield a public value, namely improving health through
the use of these products. There were those who
expressed concerns with this process, offering their
insights into the myriad of problems associated with this
burgeoning industry, specifically issues related to unsub-
stantiated health claims and safety. One investigator
described the safety issues associated with products that
emphasize natural ingredients while minimizing syn-
thetic or bioengineered ingredients:
There’s a bazillion packets for probiotics out there
now. None of them have been validated. They all have
organisms that are proprietary, you don’t know what’s
in the box. . .that you’re being fed industrially cultured
organisms that at one point in their lives were
probably related to something natural, but over the
many, many zillions of generations they’ve been
fermented. They’re no longer a wild organism, they
are an industrial organism. And we eat them and they
may be replacing normal flora. We live in a highly
processed environment and it seems that most studies
are showing that experiencing a diverse collection of
wild organisms is what we evolved from and what
helped train our immune system. We—because we’re
more industrialized, we’re probably experiencing less
exposure to organisms. Organisms live in
environments. Urban environments may be less rich
in diversity and they may be less rich in the diversity
we need. We sterilize all our vegetables, irradiate it,
and we grow our animals in mass culture. We
propagate huge outbreaks of Staph Aureus and
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All these are now becoming the organisms we’re
introduced to—monocultures of organisms. . .but we
are what we eat and we are eating things that are
industrialized. (Investigator #133)
There were investigators who described the
commercialization of dietary supplements, including pro-
biotics, in terms of “fad[s]” (Investigator #119) or “quack
medicine” (Investigator #104) not only because the claims
made on behalf of these over-the-counter products are un-
substantiated, but also because, like the products, the
health claims are manufactured for the explicit purpose of
turning a profit as opposed to actually improving the
health of the consumer. One investigator described pla-
cing the interests of the market over the interests of con-
sumers, as “I’ll bet you this is a problem we only think
about in Western capitalistic societies where we’re worried
about profit as opposed to community knowledge and
community well-being.” (Investigator #111)
Scientific debates over the effectiveness and safety of
dietary supplements seem to have had little influence on
their popularity as health products. Even though there is
a dearth of scientific evidence to support the health ben-
efits conveyed by these products [27,28], the reputed
health benefits might be the motivating factor that
underscores the continued use of these products. The
investigators with whom we spoke were aware of the
growing popularity of these products, and while con-
cerned, they were not surprised that “people still keep
using them.” (Investigator #133) In one sense, continued
use of these products may be a testament to the power
of commercialization in a health oriented consumer cul-
ture. Nettleton [29] refers to this culture as a new
paradigm of health, which emphasizes individual re-
sponsibility and lifestyle changes for ensuring good
health and preventing disease. Marketing strategies
adopt this rhetoric of individual responsibility, construct-
ing the body in a state of imbalance, providing consu-
mers with a choice to be healthy, and then encouraging
them to be proactive. Within this new paradigm of
health, marketing strategies do not need to include an
explanation of why products are good for health, they
only need to present products as simple or easy ways in
which individuals can take responsibility for their health:
“[p]eople just get excited because they think it’s going to
magically solve their health problems [and] assume that
something’s going to deliver more than it says, than it
really can.” (Investigator #119)
Public awareness of the benefits and risks of dietary
supplements
Investigators expressed strong opinions about the ways
in which the dietary supplements industry exploits andmanipulates scientific research to secure a profit, largely
at the expense of the public:
I think it’s an industry that preys on people that will
look for alternative forms of medicine – which I don’t
think are bad. . .I totally believe in holistic
medicine. . .but there are some people who, because
of the ability of advertising for those kinds of
products, can be swayed to use and spend their
money for things that are probably of no value.
(Investigator #128)
Commercial entities not only take advantage of scien-
tific research, but also of an unaware public striving to
achieve healthy bodies. Sharp and colleagues [7] reviewed
several frameworks concerning public awareness regard-
ing the benefits and risks of dietary supplements. They
introduced several safety-related considerations, specific-
ally in the use of probiotics, including the unpredictable
behavior of both naturally occurring and genetically
altered microorganisms, each of which have the potential
to produce substances or gene-behaviors that are harm-
ful to the body. Investigators contend, however, that the
allure of good health trumps the risks, and results in
these products being consumed more as an article of
faith [27]:
I think the biggest [issue] is just making sure that
people are really aware of what they’re doing. As an
example, if probiotics do become the big thing, just
making sure that people understand what they’re
taking and understand that it’s not just some magical
cure all, and that there are risks involved, also. . .[I]f
people are thinking, ‘Oh, probiotics are just a yogurt,’
or something easy like that. . .you don’t want them to
get into that mindset that ‘Oh this is something that’s
all good and there aren’t any risks associated.’ I don’t
know of any risks associated with eating Activia, but
they just need to be aware that probiotics can do
negative things, as well – can alter your microbiome
in a bad way. (Investigator #156)
Investigators were asked to share their thoughts about
the most effective ways to increase the public’s aware-
ness about the risks and benefits of dietary supplements.
Many focused on the need to use productive and under-
standable language that serves to inform, rather than in-
flame or scare, consumers:
I think interfacing with the popular media is gonna
be really key there. And that’s so difficult, because
there’s a temptation to make – you know, put out
speculative headlines based on the first
announcement of some new disease association and
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that’s not productive. (Investigator #145)
However, investigators were aware that translating and
disseminating this information has to be done in such a
way that the general or lay public will understand. This
was discussed in terms of the benefits and risks of in-
cluding these products in a daily diet, for example the
health implications of changing the balance between dif-
ferent bacterial species, as well as understanding what
this information means for them individually.
Regulation
In October 1994, the Dietary Supplement Health and
Education Act (DSHEA) was signed into law, amend-
ing the federal Food, Drug, and Cosmetic Act [30].
DSHEA loosened restrictions on developers of dietary
supplements by requiring only that the “representa-
tions or claims [are] substantiated by adequate evi-
dence to show that they are not false or misleading.”
This means that dietary supplements are not subject
to approval from the US Food and Drug Administra-
tion (FDA) prior to marketing and distribution, nor
are developers required to provide the FDA with evi-
dence to substantiate safety or effectiveness before or
after it markets its products. DSHEA places dietary
supplements in a special category under the general
umbrella of foods, not drugs, thus only requires that
every supplement be labeled a dietary supplement. The
lack of regulation was perceived as a political move
purposed to bolster the economic potential of the diet-
ary supplements industry:
The probiotics industry is not accustomed to being
regulated. There will be political agitation against it. It
will probably be a bit like the vitamin supplements
industry. . .maybe 10 or 15 years ago [the] FDA
attempted to start regulating those, and there was
furious backlash from the public. Congress passed a
law, which actually prevented [the] FDA from
regulating these supplements. . .The backlash was
both from the public, because it turns out millions
and millions of people take these things, and they
don’t want their access restricted, of course. It’s big
business, and of course big business doesn’t want to
be regulated, and so there was a backlash just on all
fronts against that. (Investigator #113)
Investigators perceived the politicization of these issues
as harmful to the public’s health:
[P]eople can sell you snake-oil treatments to deal with
your bad bacteria. . .I think if people sell stuff and they
say ‘I’m selling you,’ I don’t know, ‘cypress leaves’ Ithink you should have some guarantee that in fact
there’s cypress leaves in there, not arsenic. And just
because it’s sold by a health food store or it’s a
medical food or it’s some other crap, you should have
some assurance that it’s not going to hurt you, and
what’s really in there is in there. And that should be
across the board. (Investigator #108)
An oversight committee, ideally one that does not have
a vested economic interest and is charged primarily with
protecting public health, should validate product asser-
tions. Investigators recognized that disclosing product
ingredients is important, and measures requiring full
disclosure would prohibit the industry from misleading
assertions. Overall, their concerns were less about use of
these products, and more about how lack of regulation
has the potential to negatively affect health. This could
result in issues of where to draw the line:
So, the science that I’m in, you can see sort of ethical
implications of it when you walk through the drug
store and you look at the homeopathic medicines and
you see claims that are meant to look [like] scientific
claims that are not supported by science. And, it turns
out, that if it were a medicine, it would be regulated
in one way—that you can’t claim that the medicine
helps unless it does, because it’s medicine. But
anything that’s a food, you can make a different set of
claims without the need for validation of these claims.
The Human Microbiome Project ends up being a
whole lot of science about bacteria growing in the gut
as the body site that most closely ties to what we eat,
and the connection between what we eat and health is
potentially exploited by untold numbers of people in
the sort of quack science of homeopathic medicine –
the weak to nonexistent science of most probiotics –
the claims that every breakfast cereal company wants
to make. (Investigator #155)
Taken together, investigators’ insights into regulatory
issues centered on the intersection of the public value
and a marketable exchange value, and the implications of
this to create more harm than good. Dietary supplements
assert unsubstantiated health claims, and the current lack
of regulation ensures the dietary supplements industry
will continue to profit from these unsubstantiated claims.
These issues are directly related to the public’s health
and wellbeing, and investigators not only recognized
these issues but, overall, support stricter regulations that
place the public’s health over industry profits.
Conclusion
As previously stated, there are a number of ethical, legal
and social issues associated with human microbiome
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issues concerning the commercialization of human
microbiome research. In our examination we have con-
sidered how human microbiome research has biovalue,
illustrating the power of the dietary supplements indus-
try, and the need to find a balance between the market-
place, scientific research, and the public’s health.
Investigators’ responses are less about the authority or
expertise of biomedicine, and more about how biomed-
ical research is co-opted by commercial entities that
place profit over health. Investigators focused on the
power of the industry, namely it is not about the pro-
ducts themselves, but what the public is required to
know about the products. For example, a product that
claims “all natural ingredients” should be natural, not
engineered in a lab. The themes we identified are
intended to serve as points for discussions about the re-
lationship between scientific research and the manufac-
ture and distribution of over-the-counter dietary
supplements.
Spielmans and Parry [31] note that prior to understand-
ing the utility of scientific data “science has largely been
taken captive in the name of increasing profits” (p. 13).
Investigators’ responses suggest the commercialization of
human microbiome research, for example the production
and distribution of over-the-counter dietary supplements,
is predicated on mass consumption, not health or well-
being, in pursuit of potential profits. They suggest human
microbiome research opens the door for what we will refer
to as a commercialized intervention, or the proliferation of
commercial products that claim maintenance or restor-
ation of good health, and prevention of disease or sickness,
with the use of good bacteria. Under the current paradigm
of health that encourages individual responsibility, we
need to consider why individuals begin or continue to use
dietary supplements even when faced with evidence ques-
tioning safety or effectiveness, as well as the ethical impli-
cations of therapeutic misconception. Previous research
suggests many patients use probiotics because they con-
sider them to be natural or part of complementary and al-
ternative medicine [6]. Additionally, marketing strategies
allude to the empowering affects of dietary supplements,
such as “be proactive” or “nutrition possible,” and these
affects create hope of good health. This political economy
of hope depends on simple and quick actions or behaviors
to take responsibility for our health, and we feel empow-
ered when we spend the money on dietary supplements
that promise good health [32].
Investigators’ primary legal concerns centered on regu-
lation and policy change. Unsubstantiated claims about
the effectiveness of these products have the potential to
cause harm [33]. Substantive changes at the policy level
constitute the most effective way to regulate the current
dietary supplements industry, as well as protect thepublic’s health. Regulations previously advanced under
DSHEA [30], including preventing the dietary supple-
ments industry from deceit or manipulation, being
truthful about the actual health benefits of their pro-
ducts, requiring manufacturers to list ingredients on
each product, and how the product’s dosage is or is not
useful (i.e. does the product contain an adequate amount
of probiotic to affect positive health?), might be insuffi-
cient in the context of the current commercial market.
Manufacturers are responsible for ensuring the safety of
their products and consumers are responsible for report-
ing adverse events; the FDA, however, is responsible
only for investigating consumer claims that a product is
unsafe. Given the increasing availability of over-the-
counter dietary supplements, and the profit incentive to
produce these supplements, future research should
examine the utility of current regulations, specifically
whether or not these regulations are in place to protect
the public or the market.
There are broader ethical, legal and social implications
associated with commercialization and human micro-
biome research, which should be considered in future
research. Sharp and colleagues [7], for example, intro-
duced the environmental impact of probiotics. They
raised concerns about negative changes to the microbial
ecosystem of the human host, focusing on the different
ways in which people process these supplements and the
potential for developing immunity to probiotic bacteria.
They also discussed concerns about external environ-
mental contamination, focusing on the release of genet-
ically altered or engineered bacteria into the external
environment. Future research should consider the long-
term impact of internal and external environmental con-
tamination, exploring the ways in which the commercial
market has the potential to mitigate or exacerbate these
concerns. Additionally, recent research highlights issues
of ownership implicated in this type of research.
Hawkins and O’Doherty [34] explore the symbiotic rela-
tionship between microorganisms and the human body,
particularly in the context of private or government bio-
banks. While their analysis does not focus on issues of
commercialization, future research should consider how
this issue might play out in a commercial market. The
commercialization of human microbiome research, for
example, has the potential to give a marketable exchange
value to an individual’s microbiome or bacteria. Because
the commercial market is focused on profit, there is po-
tential for buying samples to access bacterial sequences
for commercial research (e.g. pharmaceutical research).
The purpose of this article was to fill a gap in the litera-
ture concerning the commercialization of human micro-
biome research. Our findings, while not generalizable,
suggest that investigators involved in human microbiome
research were sensitive to these issues, and were interested
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public. Future research should explore the ways in which
these issues are similarly situated within and across popu-
lations currently incorporating dietary supplements. The
issues we identified in this study are unlikely to be con-
fined to this particular group of investigators, however
through comparative research we can further examine the
extent to which these issues exist elsewhere.
Endnotes
aThe United States Food and Drug Administration defines
dietary supplements as those products taken by mouth in
the form of tablets, capsules, or foods, which contain “dietary
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